BNF:

Not listed

Status:

Do Not Prescribe (DNP), Red

Decision Date:

None

Comments

RED^1,2,3,8:  NICE TA492 - for untreated locally advanced or metastatic urothelial cancer in patients where cisplatin is unsuitable (decision date - January 2018)

RED^1,2,3,8: NICE TA520 - for the treatment of locally advanced or metastatic non-small-cell lung cancer after chemotherapy (decision date - June 2018)

RED^1,2,3,8: NICE TA525 - for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy (decision date - July 2018)

RED^1,2,3,8: NICE TA584 - in combination for treating metastatic non-squamous non-small-cell lung cancer. (Decision date - July 2019)

Do Not Prescribe (DNP)⁶: NICE TA618 - with carboplatin and nabpaclitaxel for untreated advanced non-squamous non-small-cell lung cancer. (Terminated appraisal) (Decision date - February 2020)

RED^1,2,3,8: NICE TA638 - with carboplatin and etoposide for untreated extensive stage small cell lung cancer. (Decision date  - August 2020)

RED^1,2,3,8: NICE TA639 - with nabpaclitaxel for untreated PDL1-positive, locally advanced or metastatic, triple-negative breast cancer. (Decision date  - August 2020) 

RED^1,2,3,8: NICE TA666 - Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinoma. (Decision date  - January 2021) 

Do Not Prescribe (DNP) Drug Classifications

• 6: Have NICE guidance that recommends they should not be used

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 8. NHS England commissioned – to be used in line with NHSE commissioning intentions

search again